Rohan Palekar's Net Worth
$7.19 Million
Who is Rohan Palekar?
Rohan Palekar has an estimated net worth of $7.19 Million. This is based on reported shares across multiple companies, which include 89bio, Inc., Neoleukin Therapeutics, Inc., AVANIR PHARMACEUTICALS, INC., and MEDIVATION, INC..
SEC CIK
Rohan Palekar's CIK is 0001423327
Past Insider Trading and Trends
2022 was Rohan Palekar's most active year for acquiring shares with 8 total transactions. Rohan Palekar's most active month to acquire stocks was the month of January. 2009 was Rohan Palekar's most active year for disposing of shares, totalling 10 transactions. Rohan Palekar's most active month to dispose stocks was the month of August. 2010 saw Rohan Palekar paying a total of $223,645.00 for 81,666 shares, this is the most they've acquired in one year. In 2010 Rohan Palekar cashed out on 30,000 shares for a total of $587,825.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
89bio, Inc. (ETNB) Snapshot price: $8.22
Chief Executive Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -5.69% | -27.72K |
$6.42 | -$526,903.38 | 459.17K |
Apr 1
| |||
Form 4
| -0.91% | -4.48K |
$10.76 | -$48,172.52 | 486.89K |
Feb 26
| |||
Form 4
| -0.93% | -4.60K |
$9.74 | -$44,823.48 | 491.37K |
Feb 17
| |||
Form 4
| -2.57% | -12.67K |
$8.45 | -$107,061.50 | 480.97K |
Feb 9
| |||
Form 4
| +41.56% | 144.93K |
$9.80 | -$49,666.40 | 493.65K |
Feb 1 - Feb 5
| |||
Form 4
| +15.77% | 47.49K |
$11.53 | -$317,201.83 | 348.71K |
Jan 5
| |||
Form 4
|
—
|
0
|
$6.57 | -$463,500.00 | 301.23K |
Dec 29
| |||
Form 4
| -1.47% | -4.50K |
$15.46 | -$69,585.46 | 300.95K |
Aug 17
| |||
Form 4
| +5.82% | 16.81K |
$18.95 | -$313,186.65 | 305.45K |
Jun 30
| |||
Form 4
|
—
|
0
|
$10.97 | -$271,050.00 | 286.98K |
Jun 5
| |||
Form 4
| +6.65% | 17.89K |
$15.23 | -$235,196.89 | 286.97K |
Mar 31
| |||
Form 4
| -5.28% | -15.00K |
$16.00 | -$240,000.00 | 269.08K |
Mar 23
| |||
Form 4
| -2.16% | -6.28K |
$13.97 | -$87,717.63 | 284.07K |
Feb 17
| |||
Form 4
| +34.83% | 75K |
—
|
—
| 290.35K |
Feb 9
| |||
Form 4
| -1.86% | -4.08K |
$13.24 | -$53,992.72 | 215.35K |
Feb 5
| |||
Form 4
| +11.03% | 21.81K |
$5.76 | -$66,395.52 | 219.43K |
Sep 28
| |||
Form 4
| +102.43% | 100K |
$1.93 | $193,000.00 | 197.62K |
Sep 8
| |||
Form 4
| -4.09% | -4.09K |
$5.23 | -$21,380.24 | 95.96K |
Feb 5
| |||
Form 4
| +118.22% | 54.2K |
—
|
—
| 100.05K |
Feb 17
| |||
Form 4
| +19.56% | 7.5K |
$7.05 | $52,850.00 | 45.84K |
Jan 27 - Jan 28
| |||
Form 4
| +23.33% | 7K |
$16.84 | $117,850.00 | 37K |
Jul 7 - Jul 8
| |||
Form 4
|
∞
| 30K |
—
|
—
| 30K |
Feb 5
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Feb 14
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Neurogene Inc. (NLTX) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 16
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 8
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 12
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 2
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
AVANIR PHARMACEUTICALS, INC. No price found
SVP & Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -4.72% | -15.00K |
$15.00 | -$225,000.00 | 302.81K |
Scheduled
|
Nov 28
| ||
Form 4
| +42.04% | 94.06K |
—
|
—
| 317.81K |
Nov 10
| |||
Form 4
| -4.48% | -25.00K |
$11.25 | -$287,500.00 | 533.5K |
Scheduled
|
Sep 15
| ||
Form 4
| +86.54% | 123.75K |
—
|
—
| 266.75K |
Feb 12
| |||
Form 4
| +7.52% | 10K |
$2.80 | $28,000.00 | 143K |
Dec 17
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 13
| |||
Form 4
| +8.13% | 10K |
$4.19 | $41,895.00 | 133K |
Nov 4
| |||
Form 4
| +105.00% | 63K |
—
|
—
| 123K |
Dec 17
| |||
Form 4
| +20.00% | 10K |
$2.46 | $24,598.00 | 60K |
Dec 13
| |||
Form 4
|
∞
| 50K |
—
|
—
| 50K |
Apr 3
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
MEDIVATION, INC. No price found
Chief Commercial Officer
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
$19.17 | -$86,450.00 | 16.67K |
Scheduled
|
Apr 20
| ||
Form 4
| -31.04% | -7.50K |
$16.05 | -$120,375.00 | 16.67K |
Scheduled
|
Mar 21
| ||
Form 4
| +222.21% | 16.67K |
—
|
—
| 24.17K |
Dec 15
| |||
Form 4
| +50.00% | 2.5K |
$10.91 | $27,270.00 | 7.5K |
Scheduled
|
May 17
| ||
Form 4
| -33.33% | -5.00K |
$24.65 | -$391,450.00 | 10K |
Scheduled
|
Feb 1
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Dec 15
| |||
Form 4
| -11.76% | -2.00K |
$24.49 | -$242,140.00 | 15K |
Scheduled
|
Dec 7
| ||
Form 4
| -48.17% | -9.15K |
$19.63 | -$265,998.30 | 17K |
Scheduled
|
Sep 9 - Sep 10
| ||
Form 4
| -9.52% | -2.00K |
$18.96 | -$109,466.80 | 19K |
Scheduled
|
Jun 30
| ||
Form 4
| -32.26% | -10.00K |
$16.30 | -$163,000.00 | 21K |
Scheduled
|
Mar 18
| ||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Oct 31
| |||
Form 4
|
∞
| 30K |
—
|
—
| 30K |
Jan 14 - Jan 15
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||